2022-RA-585-ESGO Come back to the future: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification
暂无分享,去创建一个
D. Giannarelli | G. Zannoni | D. Arciuolo | C. Nero | F. De Felice | E. Perrone | G. Dinoi | S. Giovanni | I. Capasso | Aniello Foresta | Fanfani Francesco | L. Domenica | Alessandro Petrecca | L. Palmieri
[1] A. Talhouk,et al. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[2] C. Genestie,et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry , 2022, British Journal of Cancer.
[3] J. Ledermann,et al. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program , 2022, International Journal of Gynecological Cancer.
[4] G. Scambia,et al. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis , 2022, Cancer.
[5] G. Scambia,et al. The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. , 2022, Gynecologic oncology.
[6] L. Insabato,et al. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis , 2022, Archives of Gynecology and Obstetrics.
[7] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[8] D. Kenwright,et al. Molecular Profiling of Endometrial Cancer: An Exploratory Study in Aotearoa, New Zealand , 2021, Cancers.
[9] C. Moiola,et al. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. , 2021, Gynecologic oncology.
[10] M. Mueller,et al. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer , 2021, medRxiv.
[11] G. Scambia,et al. Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study , 2021, Journal of gynecologic oncology.
[12] D. Santini,et al. ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification , 2021, Cancers.
[13] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[14] S. Leung,et al. The cut-off for estrogen and progesterone receptor in endometrial cancer revisited: an ENITEC collaboration study. , 2020, Human pathology.
[15] Jingxian Wu,et al. Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer , 2020, Cancer management and research.
[16] H. Putter,et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer , 2020, International Journal of Gynecological Cancer.
[17] H. Putter,et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Gilks,et al. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.
[19] T. Noda,et al. Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma. , 2019, The American journal of pathology.
[20] M. Guida,et al. TCGA molecular groups of endometrial cancer: Pooled data about prognosis. , 2019, Gynecologic oncology.
[21] P. Goodfellow,et al. Mismatch repair deficiency identifies patients with high‐intermediate–risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker , 2018, Cancer.
[22] Hongwei Zhang,et al. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification , 2018, Journal of gynecologic oncology.
[23] C. Gilks,et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups , 2018, The American journal of surgical pathology.
[24] A. Talhouk,et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] C. Marchetti,et al. Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer , 2018, International Journal of Gynecologic Cancer.
[26] K. K. van de Vijver,et al. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study , 2018, International Journal of Gynecologic Cancer.
[27] L. Pusztai,et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] Samuel Leung,et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification , 2017, The journal of pathology. Clinical research.
[29] Wei Chen,et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. , 2017, Gynecologic oncology.
[30] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[31] Shamshad Ali,et al. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma , 2016, International Journal of Gynecologic Cancer.
[32] D. Tritchler,et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Putter,et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.
[34] J. Ledermann,et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.
[35] P. Pollock,et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.
[36] H. Tsuda,et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers , 2015, Journal of gynecologic oncology.
[37] J. Marcickiewicz,et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. , 2013, European journal of cancer.
[38] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[39] J. V. Bokhman. Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.